985 related articles for article (PubMed ID: 27793510)
1. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
3. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
Zavascki AP
Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
[TBL] [Abstract][Full Text] [Related]
4. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
5. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Nation RL; Velkov T; Li J
Clin Infect Dis; 2014 Jul; 59(1):88-94. PubMed ID: 24700659
[TBL] [Abstract][Full Text] [Related]
6. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Vardakas KZ; Falagas ME
Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
8. Polymyxin B versus colistin: an update.
Cai Y; Lee W; Kwa AL
Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
[TBL] [Abstract][Full Text] [Related]
9. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
[TBL] [Abstract][Full Text] [Related]
11. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
12. History, Chemistry and Antibacterial Spectrum.
Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
[TBL] [Abstract][Full Text] [Related]
13. Optimizing use of colistin and polymyxin B in the critically ill.
Nation RL; Li J
Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
[TBL] [Abstract][Full Text] [Related]
14. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
16. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
17. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
18. Colistin, mechanisms and prevalence of resistance.
Bialvaei AZ; Samadi Kafil H
Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
[TBL] [Abstract][Full Text] [Related]
19. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL
Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324
[TBL] [Abstract][Full Text] [Related]
20. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]